Now Available: Generics Analysis: Key Patent Case Reviews

Recently published research from Datamonitor, "Generics Analysis: Key Patent Case Reviews", is now available at Fast Market Research
By: Fast Market Research, Inc.
 
 
Spread the Word
Listed Under

Tags:
* Revlimid
* Generic
* Cymbalta

Industry:
* Medical

Location:
* Massachusetts - US

Nov. 1, 2012 - PRLog -- Providing clarity regarding generic launch timing that will shape the market around Eli Lilly's antidepressant Cymbalta and Celgene's oncology drug Revlimid.

Scope
* Detailed analysis of the likely date of generic entry for Cymbalta and Revlimid
* Analysis of both products' position in their companies total prescription pharma portfolio

Highlights

Celgene is heavily dependent upon the performance of Revlimid (lenalidomide). The product generated $3.2bn in 2011, or 68.3% of the company's total sales.

The only generic version submitted so far in the US is from Natco and partner Watson. A 30-month stay runs until December 2013 and the companies have been sued for infringement of 14 patents covering Revlimid, which expire across 2016-27.

In 2012 and 2013, Cymbalta is forecast to account for 17.5% of Eli Lilly's total five major EU market sales. As such, generic launch timing will have a significant impact.

Reasons to Get this Report
* Gain clarity on when Cymbalta and Revlimid are likely to face generic competition
* Assess the threat to Eli Lilly and Celgene of these products' genericization

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/464838_generics_analysis_key_p...
------------------------------------------------------------

Report Table of Contents:

GENERIC ENTRY TIMING REVIEWS

* Key findings
* Cymbalta (duloxetine; Eli Lilly)

* EU launch of generic Cymbalta from August 2014

* Revlimid (lenalidomide; Celgene)

* Natco sued for infringement of 14 patents

APPENDIX

* References
* Exchange rates

TABLES

* Table: Cymbalta: patent protection and exclusivity in Europe
* Table: Revlimid: patent protection and exclusivity in the US
* Table: Exchange rates, 2012

FIGURES

* Figure: Cymbalta/Xeristar and Eli Lilly total five major EU market sales, 2002-17
* Figure: Revlimid and total Celgene sales, 2002-17
* Figure: US patent and exclusivity timeline relating to Revlimid
* Figure: Chemical structure of lenalidomide

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.
End
Email:***@fastmr.com Email Verified
Phone:1.800.844.8156
Zip:01267
Tags:Revlimid, Generic, Cymbalta
Industry:Medical
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share